Objective To examine factors associated with emotional well-being in women with spontaneous primary ovarian insufficiency Design Cross-sectional and case control Setting Clinical research center, national US health research facility Patient(s) Women diagnosed with spontaneous 46,XX primary ovarian insufficiency (N=100) at a mean age of 32.4 years and healthy control women of similar age (N=60) Intervention(s) Administration of validated self-reporting instruments Main Outcome Measure(s) Illness Uncertainty, Stigma, Goal Disengagement/Reengagement, Purpose in Life, Positive and Negative Affect Schedule, Center of Epidemiologic Studies Depression Scale, State-Trait Anxiety Inventory Result(s) Compared to controls, women with spontaneous primary ovarian insufficiency scored adversely on all measures of affect. Illness Uncertainty and Purpose in Life were significant independent factors associated with Anxiety (R2=0.47), Stigma and Purpose in Life were the significant independent factors associated with Depression (R2=0.51), and Goal Reengagement and Purpose in Life were significantly and independently associated with Positive Affect (R2=0.43). Conclusion(s) This evidence supports the need for prospective studies. Our findings are consistent with the hypothesis that clinicians could improve the emotional well-being of their patients with primary ovarian insufficiency by a) informing them better about their condition, b) helping them to feel less stigmatized by the disorder, and c) assisting them in developing alternative goals with regard to family planning as well as other goals.

This study examined the feasibility and effectiveness of prize-based contingency management (CM) when incentives for attendance were administered in group therapy and incentives for abstinence were administered in individual meetings. Three community substance abuse treatment programs participated in this two-phase, crossover design study. Outpatients (N = 103) entering treatment who met diagnostic criteria for cocaine, opiate, and alcohol abuse or dependence were recruited. During the standard condition, participants received standard treatment and submitted breath and urine samples that were tested for alcohol, cocaine, and opiates twice weekly during Weeks 1-6 and once weekly during Weeks 7-12. During the CM condition, participants received the same standard treatment and sample and attendance monitoring, plus the opportunity to win prizes for negative samples and treatment attendance. Demographic information and substance abuse history were evaluated at intake, and posttreatment substance use (toxicology results and self-report) was evaluated at Month 6 and Month 9 follow-up interviews. Primary outcomes were weeks retained in treatment and longest duration of sustained abstinence (LDA). LDA was significantly greater in CM-condition participants, but weeks retained did not differ between groups. Rates of substance use were lower in CM participants at Month 9 but not at Month 6. This study suggests that it is feasible to deliver incentives for attendance in group therapy, but that further research is needed to understand the modest effects on attendance. Strengths and limitations of this study are discussed.

No abstract